Home Cart Sign in  
Chemical Structure| 64-77-7 Chemical Structure| 64-77-7

Structure of Tolbutamide
CAS No.: 64-77-7

Chemical Structure| 64-77-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tolbutamide is a potassium channel blocker, sulfonylurea oral hypoglycemic drug.

Synonyms: D 860; HLS 831; Tolbutamide, Artosin, Diabetol, Orinase

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tolbutamide

CAS No. :64-77-7
Formula : C12H18N2O3S
M.W : 270.35
SMILES Code : O=S(C1=CC=C(C)C=C1)(NC(NCCCC)=O)=O
Synonyms :
D 860; HLS 831; Tolbutamide, Artosin, Diabetol, Orinase
MDL No. :MFCD00027169
InChI Key :JLRGJRBPOGGCBT-UHFFFAOYSA-N
Pubchem ID :5505

Safety of Tolbutamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Potassium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse pancreatic β-cells 5-100 µM 12 minutes Investigate the effect of tolbutamide on cytoplasmic Ca2+ concentration in β-cells, showing that tolbutamide induces a [Ca2+]i rise by closing K+-ATP channels, with response amplitude increasing with drug concentration. Br J Pharmacol. 2001 Jun;133(4):575-85
Freshly-dispersed ventromedial hypothalmic nucleus (VMHN) neurones 0.1-10 mM up to 20 min To test the effects of Tolbutamide on ATP-K+ channel currents, showing no significant inhibition. Br J Pharmacol. 1990 Nov;101(3):531-40

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Glucoreceptive VMHN neurones in hypothalamic slices Superfusion 0.1 mM Single application, lasting 1 min To test the effects of Tolbutamide on glucoreceptive neurones, showing it depolarized the cells and increased membrane resistance. Br J Pharmacol. 1990 Nov;101(3):531-40
Mice Anesthetized mice Intravenous injection 1800 mg/kg Single injection To study the effect of tolbutamide on the electrical activity of mouse pancreatic β-cells, showing that tolbutamide transformed the oscillatory pattern into continuous electrical activity, associated with a decrease in blood glucose concentration. Br J Pharmacol. 1998 Feb;123(3):443-8
Rats Wistar rats Intravenous injection 50 mg/kg Single dose To study the pharmacokinetic interactions of tolbutamide, including the effects of enzyme induction and inhibition. Results showed that phenobarbitone pretreatment significantly decreased the half-life and AUC of tolbutamide and increased clearance and volume of distribution, while primaquine and cimetidine significantly increased half-life and AUC and decreased clearance. Br J Pharmacol. 1984 Mar;81(3):557-62

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02456428 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02476760 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02475499 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02414958 Diabetes Mellitus, Type 1 Phase 3 Completed - -
NCT02414958 - Completed - -
NCT03492580 - Completed - United States, New Jersey ... More >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 Less <<
NCT03071692 Type2 Diabetes ... More >> Dyslipidemia Less << Phase 3 Recruiting May 2022 -
NCT01475461 Type 2 Diabetes Mellitus Phase 2 Completed - -
NCT01475461 - Completed - -
NCT01068860 Type 2 Diabetes Mellitus ... More >> Impaired Glucose Tolerance Less << Phase 2 Completed - -
NCT00741468 Drug Interactions Phase 1 Completed - United States, New Jersey ... More >> Clinical Research Center Advanced Biomedical Research Inc. Hackensack, New Jersey, United States, 07601 Less <<
NCT01068860 - Completed - -
NCT00741468 - Completed - -
NCT01188525 Healthy Volunteers Phase 1 Completed - France ... More >> Center of clinical investigation Paris, France, 75018 Less <<
NCT00082238 Cystic Fibrosis ... More >> Diabetes Mellitus Less << Not Applicable Completed - United States, Texas ... More >> University of Texas Southwestern Dallas, Texas, United States, 75390-9063 Less <<
NCT03723395 Drug-drug Interaction Phase 1 Recruiting November 2018 United States, Florida ... More >> Covance Clinical Research Unit Recruiting Daytona Beach, Florida, United States, 32117 Contact: Michelle Saint Pierre    386-366-6428    michelle.saintpierre@covance.com    Principal Investigator: Hugh Coleman          United States, Texas Covance Clinical Research Unit Recruiting Dallas, Texas, United States, 75247 Contact: Iona Tihina    469-513-6716    Ioana.Tihina@covance.com    Principal Investigator: Jennifer Zon Less <<
NCT02819102 Hereditary Angioedema Phase 1 Completed - United Kingdom ... More >> Quotient Clinical Ltd Ruddington, Nottingham, United Kingdom, NG11 6JS Less <<
NCT01218620 Adult Solid Neoplasm Phase 1 Completed - United States, Wisconsin ... More >> University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Less <<
NCT02133118 - Completed - Netherlands ... More >> Isala Zwolle, Overijssel, Netherlands, 8000 AB Less <<
NCT01237522 Metformin Org... More >>anic Cation Transporter 2 Polymorphism,Single Nucleotide Less << Phase 4 Completed - Denmark ... More >> Institute of Public Health, Clinical Pharmacology, University of Southern Denmark Odense, Denmark, 5000 Less <<
NCT01260844 Moderate to Severe Plaque Psor... More >>iasis Less << Phase 1 Withdrawn(Study stopped) - -
NCT00185003 Endotoxemia Phase 1 Completed - -
NCT00738088 Diabetes Mellitus, Type 2 Phase 4 Terminated(Following Regulator... More >> inspection in 2009, study terminated as inadequate approvals were in place) Less << - United Kingdom ... More >> NHS Tayside Dundee, United Kingdom, DD1 9SY Less <<
NCT01061112 - Unknown June 2014 United States, Minnesota ... More >> Clinical and Translational Science Institute Minneapolis, Minnesota, United States, 55414 Less <<
NCT02473627 Healthy Phase 1 Completed - United Kingdom ... More >> London, United Kingdom, NW10 7EW Less <<
NCT00369304 Healthy Subjects Phase 1 Completed - -
NCT03457597 Healthy Phase 1 Completed - United States, Arizona ... More >> Celerion Tempe, Arizona, United States, 85283 Less <<
NCT02291666 Type 2 Diabetes Phase 4 Recruiting October 2019 Canada, Quebec ... More >> Centre hospitalier de l'Université de Montréal (CHUM) Recruiting Montreal, Quebec, Canada, H2X0A9 Contact: Veronique Michaud, BPharm, PhD    514-8908000 ext 15812    v.michaud@umontreal.ca    Contact: Jacques Turgeon, BPharm,PhD    514-8908045    jacques.turgeon@umontreal.ca    Principal Investigator: Veronique Michaud, BPharm,PhD          Sub-Investigator: Jean-Louis Chiasson, MD          Sub-Investigator: Jacques Turgeon, BPharm,PhD Less <<
NCT02515526 AOD Effects and Consequences Not Applicable Unknown December 2016 Germany ... More >> Department of Pharmacology I, University Hospital Cologne Cologne, NRW, Germany, 50931 Less <<
NCT03103568 Drug Drug Interaction Phase 1 Completed - Germany ... More >> PAREXEL EPCU Berlin Berlin, Germany, 14050 Less <<
NCT01147887 Healthy Phase 1 Completed - Belgium ... More >> Merksem, Belgium Less <<
NCT01525628 Hepatitis C, Chronic Phase 1 Completed - United States, California ... More >> 1241.27.0006 Boehringer Ingelheim Investigational Site La Mesa, California, United States United States, Maryland 1241.27.0005 Boehringer Ingelheim Investigational Site Rockville, Maryland, United States United States, New Jersey 1241.27.0004 Boehringer Ingelheim Investigational Site Marlton, New Jersey, United States United States, Pennsylvania 1241.27.0003 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States United States, Utah 1241.27.0001 Boehringer Ingelheim Investigational Site Salt Lake City, Utah, United States Canada, British Columbia 1241.27.0200 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada 1241.27.0600 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada 1241.27.0700 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada 1241.27.0400 Boehringer Ingelheim Investigational Site Victoria, British Columbia, Canada Canada, Ontario 1241.27.0100 Boehringer Ingelheim Investigational Site London, Ontario, Canada 1241.27.0300 Boehringer Ingelheim Investigational Site Ottawa, Ontario, Canada Canada, Quebec 1241.27.0500 Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada Germany 1241.27.4901 Boehringer Ingelheim Investigational Site Frankfurt am Main, Germany 1241.27.4907 Boehringer Ingelheim Investigational Site Köln, Germany 1241.27.4903 Boehringer Ingelheim Investigational Site Leipzig, Germany 1241.27.4906 Boehringer Ingelheim Investigational Site Mainz, Germany Less <<
NCT00930306 Chronic Pain Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Research Site Manchester, United Kingdom Less <<
NCT03716427 Healthy Volunteers Phase 1 Completed - United States, Michigan ... More >> Jasper Clinic Kalamazoo, Michigan, United States, 49007 Less <<
NCT01525628 - Completed - -
NCT02182401 Healthy Phase 1 Terminated - -
NCT02211079 Healthy Phase 1 Completed - Netherlands ... More >> Groningen, Netherlands Less <<
NCT01185548 Lymphoma Adva... More >>nced Cancer Less << Phase 1 Terminated(Terminated based on... More >> safety results from another trial) Less << - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Cardiff, South Glamorgan, United Kingdom, CF14 2TL For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sheffield, Trent, United Kingdom, S10 2SJ For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS9 7TF For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leicester, United Kingdom, LE1 5WW For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. London, United Kingdom, WC1E 6BT Less <<
NCT03291288 Drug Interaction Potential Phase 1 Active, not recruiting March 2019 United States, Arizona ... More >> HonorHealth Scottsdale, Arizona, United States, 85258 University of Arizona Tucson, Arizona, United States, 85719 United States, California Stanford University Palo Alto, California, United States, 94304 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, New York Northwell Health Lake Success, New York, United States, 10042 United States, Texas Mary Crowley Cancer Research Dallas, Texas, United States, 75230 Netherlands Leids Universitair Medisch Centrum Leiden, Netherlands, 2333 ZA New Zealand Christchurch Hospital NZ Christchurch, New Zealand, 8011 Taiwan National Taiwan University Hospital Taipei, Taiwan, 10002 Less <<
NCT01185548 - Terminated(Terminated based on... More >> safety results from another trial) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.49mL

3.70mL

1.85mL

36.99mL

7.40mL

3.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories